Home Featured Page 100

Featured

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

William Leonard Pickard participating in celebration for Sasha Shulgin’s new book ‘The Nature of Drugs’

PTSF49 – MDMA For Alcoholism, The Placebo Effect, and Ceremonial Magicians

Bright Minds Biosciences Announces Closing of $4 Million Unit Offering

The Therapeutic Effects of Psychedelics: 2A or Not 2A? – Part...

PT319 – Kole – Activism and Trust: A Cautionary Tale From...

COMPASS Pathways appoints Kabir Nath as Chief Executive Officer

New 3D Structures of Cannabinoid Receptor Inform Safer Drug Design

Psychedelic Science Leader Eleusis to Become Public Company in Merger with...

Clearmind Medicine Featured in “Psychedelics Tonight,” Streaming on ALTRD.TV

Psychedelic Bulletin: MAPS’ $70m Investment Vehicle; atai’s Increased Stake in COMPASS;...

PT320 – Anne Philippi – The New Health Club, Intergenerational Trauma,...

New Psychedelic Entactogens: Designer Drugs Produce Designer Effects

1...99100101...292 Page 100 of 292

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on...

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

William Leonard Pickard participating in celebration for Sasha Shulgin’s new book ‘The Nature of Drugs’

PTSF49 – MDMA For Alcoholism, The Placebo Effect, and Ceremonial Magicians

Bright Minds Biosciences Announces Closing of $4 Million Unit Offering

The Therapeutic Effects of Psychedelics: 2A or Not 2A? – Part...

PT319 – Kole – Activism and Trust: A Cautionary Tale From...

COMPASS Pathways appoints Kabir Nath as Chief Executive Officer

New 3D Structures of Cannabinoid Receptor Inform Safer Drug Design

Psychedelic Science Leader Eleusis to Become Public Company in Merger with...

Clearmind Medicine Featured in “Psychedelics Tonight,” Streaming on ALTRD.TV

Psychedelic Bulletin: MAPS’ $70m Investment Vehicle; atai’s Increased Stake in COMPASS;...

PT320 – Anne Philippi – The New Health Club, Intergenerational Trauma,...

New Psychedelic Entactogens: Designer Drugs Produce Designer Effects

EDITOR PICKS

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on...

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY